215 related articles for article (PubMed ID: 23377400)
1. Progressive multifocal leukoencephalopathy and reversible progressive leukoencephalopathy syndrome in dermatologic therapy.
Ladizinski B; Heller MM; Bhutani T; Zitelli KB; Koo JY
J Drugs Dermatol; 2013 Feb; 12(2):e20-4. PubMed ID: 23377400
[TBL] [Abstract][Full Text] [Related]
2. Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients.
Kothary N; Diak IL; Brinker A; Bezabeh S; Avigan M; Dal Pan G
J Am Acad Dermatol; 2011 Sep; 65(3):546-551. PubMed ID: 21514689
[TBL] [Abstract][Full Text] [Related]
3. Progressive multifocal leukoencephalopathy and antipsoriatic drugs: assessing the risk of immunosuppressive treatments.
Di Lernia V
Int J Dermatol; 2010 Jun; 49(6):631-5. PubMed ID: 20618466
[TBL] [Abstract][Full Text] [Related]
4. Immunosuppressive therapy in dermatology and PML.
Sterry W; Bagot M; Ferrandiz C; Kragballe K; Papp K; Stingl G
J Dtsch Dermatol Ges; 2009 Jan; 7(1):5. PubMed ID: 19138293
[No Abstract] [Full Text] [Related]
5. Progressive multifocal leukoencephalopathy in two psoriasis patients treated with efalizumab.
Gadzia J; Turner J
J Drugs Dermatol; 2010 Aug; 9(8):1005-9. PubMed ID: 20684152
[TBL] [Abstract][Full Text] [Related]
6. [Targeted therapy and progressive multifocal leukoencephalopathy (PML): PML in the era of monoclonal antibody therapies].
Takao M
Brain Nerve; 2013 Nov; 65(11):1363-74. PubMed ID: 24200614
[TBL] [Abstract][Full Text] [Related]
7. Progressive multifocal leukoencephalopathy: an unexpected complication of modern therapeutic monoclonal antibody therapies.
Tavazzi E; Ferrante P; Khalili K
Clin Microbiol Infect; 2011 Dec; 17(12):1776-80. PubMed ID: 22082208
[TBL] [Abstract][Full Text] [Related]
8. Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies.
Molloy ES; Calabrese LH
Arthritis Rheum; 2012 Sep; 64(9):3043-51. PubMed ID: 22422012
[TBL] [Abstract][Full Text] [Related]
9. Risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis.
Faulkner M
Expert Opin Drug Saf; 2015; 14(11):1737-48. PubMed ID: 26394704
[TBL] [Abstract][Full Text] [Related]
10. Signals of progressive multifocal leukoencephalopathy for immunosuppressants: a disproportionality analysis of spontaneous reports within the US Adverse Event Reporting System (AERS).
Schmedt N; Andersohn F; Garbe E
Pharmacoepidemiol Drug Saf; 2012 Nov; 21(11):1216-20. PubMed ID: 22821419
[TBL] [Abstract][Full Text] [Related]
11. Progressive multifocal leukoencephalopathy: report of three cases in HIV-negative hematological patients and review of literature.
Pelosini M; Focosi D; Rita F; Galimberti S; Caracciolo F; Benedetti E; Papineschi F; Petrini M
Ann Hematol; 2008 May; 87(5):405-12. PubMed ID: 18064459
[TBL] [Abstract][Full Text] [Related]
12. A mechanism-based classification of dermatologic reactions to biologic agents used in the treatment of cutaneous disease: Part 1.
Bremmer M; Deng A; Gaspari AA
Dermatitis; 2009; 20(4):182-92. PubMed ID: 19804694
[TBL] [Abstract][Full Text] [Related]
13. Efalizumab discontinuation: a practical strategy.
Pugashetti R; Koo J
J Dermatolog Treat; 2009; 20(3):132-6. PubMed ID: 19459081
[TBL] [Abstract][Full Text] [Related]
14. A risk classification for immunosuppressive treatment-associated progressive multifocal leukoencephalopathy.
Chahin S; Berger JR
J Neurovirol; 2015 Dec; 21(6):623-31. PubMed ID: 25404234
[TBL] [Abstract][Full Text] [Related]
15. Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk?
Molloy ES; Calabrese LH
Autoimmun Rev; 2008 Dec; 8(2):144-6. PubMed ID: 18700172
[TBL] [Abstract][Full Text] [Related]
16. The Risk of Progressive Multifocal Leukoencephalopathy in the Biologic Era: Prevention and Management.
Molloy ES; Calabrese CM; Calabrese LH
Rheum Dis Clin North Am; 2017 Feb; 43(1):95-109. PubMed ID: 27890176
[TBL] [Abstract][Full Text] [Related]
17. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
[TBL] [Abstract][Full Text] [Related]
18. Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis.
Fleischmann RM
Arthritis Rheum; 2009 Nov; 60(11):3225-8. PubMed ID: 19877057
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project.
Carson KR; Focosi D; Major EO; Petrini M; Richey EA; West DP; Bennett CL
Lancet Oncol; 2009 Aug; 10(8):816-24. PubMed ID: 19647202
[TBL] [Abstract][Full Text] [Related]
20. Progressive multifocal leukoencephalopathy in liver transplant recipients: a case report and review of the literature.
Verhelst X; Vanhooren G; Vanopdenbosch L; Casselman J; Laleman W; Pirenne J; Nevens F; Orlent H
Transpl Int; 2011 Apr; 24(4):e30-4. PubMed ID: 21134241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
